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The removal of neurotransmitters by their transporters in presynaptic nerve terminals and glial cells plays an important role in the termination 
of synaptic transmission. Many neurotransmitter t ansporters, which are sodium- and chloride-coupled, have been cloned and shown to constitute 
a large superfamily. Glutamate is the major excitatory neurotransmitter in the central nervous system. If not efficiently removed, it causes death 
of neuronal cells. Its transporter couples the flow of glutamate to that of sodium and potassium. Recently three different but related glutamate 
transporters have been cloned, which have no significant homology to the members of the superfamily. 
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1. INTRODUCTION 
The overall process of synaptic transmission is termi- 
nated by high-affinity sodium-dependent transport of 
the neurotransmitters from the synaptic cleft [ 1,2]. This 
includes the neurotransmitters y-aminobutyric acid 
(GABA), L-glutamate, glycine, dopamine, serotonin 
and norepinephrine. Another termination mechanism is 
observed with cholinergic transmission. After dissocia- 
tion from its receptor, acetylcholine is hydrolysed into 
choline and acetate. The choline moiety is then recov- 
ered by a sodium-dependent transport. As the concen- 
tration of the transmitters in the nerve terminals is much 
higher than in the cleft, typically by 4 orders of magni- 
tude, energy input is required. The transporters which 
are located in the plasma membranes of nerve endings 
and glial cells achieve this by coupling the flow of neu- 
rotransmitters to that of sodium. The (Na’,K’)-ATPase 
generates an inwardly-directed electrochemical sodium 
gradient which is utilized by the transporters to drive 
‘uphill’ transport of the neurotransmitters (reviewed in 
13-m 
These transport systems have been investigated in 
detail by using plasma membranes obtained upon os- 
motic shock of synaptosomes. It appears that these 
transporters are coupled not only to sodium, but also 
to additional ions like potassium or chloride. 
These transporters are of considerable medical inter- 
est. Since they function to regulate neurotransmitter 
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activity by removing it from the synaptic cleft, specific 
transporter inhibitors can be potentially used as novel 
drugs for neurological disease. For instance, attenua- 
tion of GABA removal will prolong the effect of this 
inhibitory transporter, thereby potentiating its action. 
Thus, inhibitors of GABA transport could represent a 
novel class of anti-epileptic drugs. Well-known inhib- 
itors which interfere with the functioning of biogenic 
amine transporters include anti-depressant drugs and 
stimulants uch as amphetamines and cocaine. The neu- 
rotransmitter glutamate, at excessive local concentra- 
tions, causes cell death, by activating NMDA receptors 
and subsequent calcium entry. The transmitter has been 
implicated in neuronal destruction in ischaemia, epi- 
lepsy, stroke, amyotropic lateral sclerosis and Hunting- 
ton’s disease. Neuronal and glial glutamate transporters 
may have a critical role in preventing glutamate from 
acting as an exitotoxin [6,7]. 
In the last few years major advances in the cloning of 
these neurotransmitter transporters have been made. 
After the GABA transporter was purified [8], the ensu- 
ing protein sequence information was used to clone it 
[9]. Subsequently the expression cloning of a norep- 
inephrine transporter [lo] provided evidence that these 
two are the first members of a novel superfamily of 
neurotransmitter transporters. This led, using polym- 
erase chain reaction (PCR) and other technologies rely- 
ing on sequence conservation, to the isolation of a grow- 
ing list of neurotransmitter transporters (reviewed in 
[l l-131). This list includes various subtypes of GABA 
transporters as well as those for all the above-men- 
tioned neurotransmitters, except for glutamate. All of 
the members of this superfamily are dependent on so- 
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dium and chloride and by analogy with the GABA 
transporter [141 are likely to cotransport their transmit- 
ter with both sodium and chloride. Interestingly so- 
dium-dependent glutamate transport is not chloride 
dependent, but rather is countertransported with potas- 
sium [15,16]. In the last few months three distinct but 
highly related glutamate transporters have been cloned 
[17-191. These transporters represent a distinct family 
of transporters. 
2. THE SUBSTRATES OF THE L-GLUTAMATE 
TRANSPORTER 
The mechanism of sodium-dependent L-glutamate 
transport has been studied initially using tracer flux 
studies employing radioactive glutamate. These studies 
indicated that the process is electrogenic, with the posi- 
tive charge moving in the direction of the glutamate 
[l&20]. This observation suggested that it is possible to 
monitor L-glutamate transport electrically using the 
whole-cell patch-clamp technique [21]. This latter tech- 
nique has the advantage that the membrane potential 
can be controlled throughout the transport experi- 
ments. It is reassuring that the results obtained with 
both techniques are in harmony with each other (re- 
viewed in [5] and [22]), and they are summarized here 
briefly. In addition to L-glutamate, D- and L-aspartate 
are transportable substrates with affinities in the lower 
micromolar range. The system is stereospecific with re- 
gard to glutamate, the o-isomer being a poor substrate. 
Glutamate uptake is driven by an inwardly directed 
sodium ion gradient and at the same time potassium is 
moving outward. The potassium movement is not due 
to a passive movement in response to the charge carried 
by the transporter. Rather it is an integral part of the 
translocation cycle catalyzed by the transporter. Its role 
is further described below (section 4). Very recently ev- 
idence has been presented that another ionic species is 
countertransported (in addition to potassium), namely 
hydroxyl ions [23]. 
3. STOICHIOMETRY 
The first-order dependence of the carrier current on 
internal potassium [24], together with the well-known 
first order dependence on external rglutamate and 
sigmoid dependence on external sodium, suggest a stoi- 
chiometry of 3 Na+: 1 K+: 1 glutamate- [15,24]. This 
stoichiometry suggests that one positive charge is mov- 
ing inward per glutamate anion entering the cell. If an 
hydroxyl anion is countertransported as well [23], the 
stoichiometry could be 2 Na+: 1 K’: 1 glutamate: 1OH-, 
and transport would still be electrogenic. A stoichio- 
metry of 2 Na’:l glutamate is also favored by direct 
experimental evidence obtained by kinetic [25] and ther- 
modynamic methods [26]. 
96 
4. BINDING ORDER OF THE SUBSTRATES: THE 
ROLE OF POTASSIUM 
Just as influx of glutamate is coupled to etIiux of 
potassium, etllux of glutamate can be induced by in- 
creasing external potassium [27]. This phenomenon is 
also believed to underlie brain damage during anoxial 
ischemia. Under such pathological conditions the exter- 
nal potassium concentration rises and this causes re- 
lease of glutamate by reversal of the glutamate trans- 
porter. If these increased extracellular glutamate levels 
persist, the neurons die probably because of excessive 
calcium influx through NMDA receptor channels. Ra- 
diotracer studies showed that there is another, potas- 
sium-independent, way to cause the e&x of radioactive 
L-glutamate, namely by addition of unlabelled external 
L-glutamate (exchange [16]). This suggests that the glu- 
tamate translocation step is distinct from that of potas- 
sium. In other words it consists of two stages: (1) 
translocation of sodium and L-glutamate, and (2) reori- 
entation of the binding sites upon binding and translo- 
cation of potassium [161. The binding order of the sub- 
strates was probed by comparing the ion-dependence of 
net flux with that of exchange (or counter-flow) [16,28]. 
According to the model (Fig. l), during infhtx (steps 
1-8) the two or three sodium ions (see section 3) bind 
first followed by one glutamate anion. This results in the 
formation of the translocation complex. Upon translo- 
cation of the two substrates to the inside, glutamate is 
released first followed by sodium (although a random 
order on the inside cannot be rigorously excluded). Sub- 
sequently potassium binds on the inside. Upon translo- 
cation of the potassium-loaded transporter to the out- 
side, the potassium is released and a new influx cycle 
can commence [28]. EfRux of glutamate operates by a 
reversal of these steps (going clockwise). Hydroxyl 
anions could be translocated concomitant with gluta- 
mate (steps 24) or with potassium (steps 6-8). In addi- 
tion it appears that internal potassium is required for 
the optimal functioning of the transporter, probably by 
an allosteric mechanism [28]. 
5. REGULATION OF TRANSPORTER ACTIVITY 
Termination of glutamergic transmission is a key 
process which is likely to be subject to regulation. Thus 
far our knowledge on this is fragmentary. It has been 
shown that arachidonic acid can inhibit glutamate 
transport [29,30]. Furthermore, short-term exposure of 
glial but not of neuronal cells to phorbol esters stimu- 
lates glutamate transport about 2 fold [31]. This effect 
is blocked by protein kinase C inhibitors, suggesting 
that it is a consequence of phosphorylation of the trans- 
porter. At this time we can only speculate on a sequence 
of events which makes physiological sense. The cells 
containing the transporter must somehow sense that 
extracellular glutamate is too high, e.g. by the 
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metabotropic receptor. At the fine glial processes which 
are located in close proximity to the synapse, glutamate 
could activate its metabotropic receptor leading to gen- 
eration of diacylglycerol, which in turn can activate 
protein kinase C. This causes increased transporter ac- 
tivity and thus more efficient removal of the transmitter. 
6. RECONSTITUTION AND PURIFICATION 
A sodium- and potassium-coupled L-glutamate trans- 
porter from rat brain has been purified to near homoge- 
neity using reconstitution of transport as an assay [32]. 
The properties of the pure transporter are fully pre- 
served. They include ion dependence, electrogenicity, 
affinity, substrate specificity, and stereospecificity. 
SDS-PAGE revealed one main band with an apparent 
molecular mass of around 80 kDa and a few minor 
bands. Later the apparent molecular mass of the main 
band was corrected to 73 kDa [33]. Comparison of pol- 
ypeptide composition with L-glutamate transport activ- 
ity throughout the fractionation procedure reveals that 
only the 73 kDa band can be correlated with activity. 
Polyclonal antibodies against the 73 kDa band were 
able to selectively immunoprecipitate the 73 kDa pol- 
ypeptide as well as most of the L-glutamate transport 
activity, as assayed upon reconstitution, from crude de- 
tergent extracts of rat brain membranes [33]. Thus, the 
73 kDa polypeptide represents the L-glutamate trans- 
porter, a conclusion reinforced by its cloning [18]. 
Using the antibodies raised against the glutamate 
transporter, the immunocytochemical localization of 
the transporter was studied at the light and electron 
microscopic level in the rat central nervous system. In all 
regions examined (including cerebral cortex, caudato- 
putamen, corpus callosum, hippocampus, cerebellum, 
spinal cord) it was found to be located in glial cells 
rather than in neurons. In particular, fine astrocytic 
processes were strongly stained. Putative glutamatergic 
axon terminals appeared nonimmunoreactive [33]. The 
uptake of glutamate by such terminals (for which there 
is strong previous evidence) therefore may be due to a 
subtype of glutamate transporter different from the glial 
transporter. Using a monoclonal antibody raised 
against this transporter, a similar glial localization of 
the transporter was found [34]. 
7. MOLECULAR CLONING AND PREDICTED 
STRUCTURE OF THE TRANSPORTERS 
Transporters for many neurotransmitters were 
cloned on the assumption that they are related to the 
GABA [9] and norepinephrine [lo] transporters (re- 
viewed in [11-l 31). This approach was unsuccessful for 
the glutamate transporter. Very recently three different 
glutamate transporters were cloned using different ap- 
proaches: GLAST [17], GLT-1 [18] and EAAC 1 [19]. 
The former two appear to be of glial [17,33], the latter 
out in 
OK+),- c(K+) 
t + U-n I 
C(Na+h i-L glut (4) 
-&Ntih glut 
(3) 
Fig. 1. A model for the mechanism of L-glutamate translocation. The 
details are described in the text. As indicated, n = 3 or 2, m = 1. Not 
indicated is the possible countertransport of one hydroxyl ion per 
glutamate. Reprinted with permission from Biochemistry 29 (1990) 
11209-11214. 
of neuronal origin [19]. Indeed, the three transporters 
are not related to the above superfamily [17-191. On the 
other hand, they are very similar to each other (Fig. 2), 
displaying- 50% identity and - 60% similarity. They also 
appear to be related to the proton-coupled glutamate 
transporter from E. coli and other bacteria @It-P [35]) 
and the dicarboxylate transporter (d&-A [36]) of 
Rhizobium meliloti. In these cases the identities are 
around 25-30%. Thus, they form a distinct family. They 
contain between 50@600 amino acids. GLT-1, which 
encodes the glutamate transporter which was purified 
[18,32,33], has 573 amino acids and a relative molecular 
mass of 64 kDa, in good agreement with the value of 
65 kDa of the purified and deglycosylated transporter 
[33]. Hydrophaty plots are relatively straightforward at 
the amino terminal side of the protein and the three 
different groups have predicted 6 transmembrane a- 
helices at very similar positions (Fig. 2 and [ 17-191). On 
the other hand, there is much more ambiguity at the 
carboxyl side where 0 [ 17],2 [ 181 or 4 [ 191 a-helices have 
been predicted. However, all three groups note uncer- 
tainty in assigning transmembrane a-helices in this part 
of the protein, taking into account alternative possibili- 
ties including membrane spanning p-sheets [17]. It is 
clear that experimental approaches to delineate their 
topology are badly needed. The most similar part of 
glt-P is also included in the alignment. In this stretch, 
out of 98 amino acids, 36 are identical in all 4 trans- 
porters and another 18 are similar. By themselves the 
three neurotransmitter transporters display a - 75% 
identity and close to 90% similarity in this stretch. Espe- 
cially striking is the stretch of 7 amino acids 
AAI(V)FIAQ (407413, GLT- 1 numbering). It is tempt- 
ing to speculate that the only polar residue, glutamine 
(Q), could be involved in glutamate binding. The pres- 
97 
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TINMDGTALY EALAAIVIAQ VNNFDLNFGQ IITISITATA ASIGAAGIPQ 
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KLSKKELEQM DVSSEVNIVN PFALESATLD NEDSDTKKSY ..INGGFAVD 
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. . . . . . . . . . . . . . . . . . 
551 583 
KPVADSETKM . _._ ..___ ___ 
KSDTISFTQT SQF....... . . . . . . . . . . . 
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. . . . . . . . . . . . . . . . . . . . 
Ftg. 2. Alignment of glutamate transporter sequences. Sequences are taken from the following references: GLAST [17]; EAAC 1 [19], GLT-1 [18] 
and glt-P [35]. Two sequencing errors discovered after the publication of GLT-1 [18] have resulted in a correctton of the amino acid sequence, 
between amino acids 260 and 289, as shown in the figure. Only the part of glt-P which is most homologous to the three neurotransmitter transporters, 
is displayed. The first six putative transmembrane a-helices, as assigned in the original publications, are underlined by bars. The other assigned 
helices, which are ambiguous, are underlined by interrupted bars. Gaps are introduced to optimize identical sequence positions. Putative phospho- 
rylation sites, conserved in the three neurotransmitter t ansporters, are overlined once for protein kinase C sites and twice for the protein kinase 
A site. The conserved charged amino acids, lysine in helix 5 and histidine in helix 6, are boxed. 
ence of charged amino acids, located in the membrane 
and conserved in the three transporters, e.g. lysine in 
helix 5 and histidine in helix 6 (Fig. 2), may point to 
their importance. However, this will have to be clarified 
by site-directed mutagenesis. One of the proposed mod- 
els (GLT-1, [18]) is shown here (Fig. 3) to point out 
some other structural features. These include potential 
glycosylation sites in the large extracellular loop be- 
tween helices 3 and 4 and putative protein kinase A and 
C phosphorylation sites. Two of the putative protein 
kinase C phosphorylation sites and a potential protein 
kinase A site are conserved in all three transporters 
(overlined in Fig. 2). This could hint that one or both 
of them are used physiologically. On the other hand the 
observation that phorbol esters activate glutamate 
transport in glial but not in neuronal cells [31] could 
argue against this. Again, site-directed mutagenesis 
studies are likely to clarify this issue. 
In addition to the heterogeneity of glutamate trans- 
porters revealed by molecular cloning, recent pharma- 
cological studies also provide evidence for this [3740]. 
A careful pharmacological characterization of the three 
cloned glutamate transporters should indicate if there 
are more of these transporters yet to be cloned. Further- 
more, it is likely that the new family will not necessarily 
be limited to glutamate transporters, but includes others 
98 
NH, lnlracollular 
OH 
Fig. 3. Schematic representation of the L-glutamate transporter GLT- 
1 showing its proposed orientation in the plasma membrane. Putative 
transmembrane segments are shown as rectangles. One putative pro- 
tein kinase A and three putative protein kinase C phosphorylation 
sites are indicated by an arrowhead and arrows, respectively. The 
remaining two potential protein kinase C sites in the putative xtracel- 
lular loop between helices 3 and 4 are not shown. The two putative 
glycosylation sites are also located on this loop and are indicated as 
branched lines. Adapted from Nature 360 (1992) 464467. 
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transporting different neurotransmitters or other sol- [lo] Pacholczyk, T., Blakely, R.D. and Amara, S.G. (1991) Nature 
utes. 350, 35&353. 
8. CONCLUSIONS 
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Recent progress in molecular cloning of glutamate 
transporters has revealed that, contrary to expectations 
by many, they do not belong to the recently character- 
ized superfamily of neurotransmitter transporters. The 
members of the latter family are sodium- and chloride- 
coupled. On the other hand, the family of glutamate 
transporters are coupled to sodium and potassium, and 
this should of course be reflected in structural differ- 
ences. A major challenge is to reveal the structural basis 
of this difference in ion specificity as well as other fea- 
tures, including substrate binding and regulatory do- 
mains. Other issues to be solved are identification of 
other family members and the topology of the trans- 
porters. The powerful combination of biochemical and 
molecular biological approaches hould be able to shed 
light on many of these issues. 
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